BioCentury
ARTICLE | Company News

AbGenomics Corp., Boehringer Ingelheim deal

June 13, 2005 7:00 AM UTC

AbGenomics granted Boehringer Ingelheim an exclusive worldwide license to develop and commercialize antibody 168. The humanized MAb initially will be developed for autoimmune indications. The companie...